Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.

NCT00461929 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00461929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00461929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.
Lead sponsor
University Health Network, Toronto
Phase
Phase 4
Overall status
Terminated
Start date
February 28, 2005
Completion date
December 31, 2008
Enrollment
68 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chromosome abnormality, chronic myeloid leukemia, gastrointestinal stromal cell tumors